TCG Crossover Management »

Taysha Gene Therapies shares owned by TCG Crossover Management

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by TCG Crossover Management from 13F filings

Historical chart of TCG Crossover Management investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by TCG Crossover Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $35M 11M 3.16

More positions owned by TCG Crossover Management

Structure Therapeutics Adrs (GPCR)
Cogent Biosciences Comm (COGT)
Geron Corp Comm (GERN)
AN2 Therapeutics Comm (ANTX)
Savara Comm (SVRA)
Taysha Gene Therapies Comm (TSHA)
Kalvista Pharmaceuticals Comm (KALV)
Inhibrx Comm (INBX)
Aerovate Therapeutics Comm (AVTE)
Icosavax Comm
Compass Pathways Adrs (CMPS)
Ventyx Biosciences Comm (VTYX)
Tyra Biosciences Comm (TYRA)
Madrigal Pharmaceuticals Comm (MDGL)
Silence Therapeutics Adrs (SLN)

View all positions for TCG Crossover Management

Top funds holding Taysha Gene Therapies

FMR
RA Capital Management
VR Adviser
Vanguard Group
Morgan Stanley
venBio Select Advisor
Baker Bros. Advisors
Artal Group
Millennium Management
Octagon Capital Advisors
BlackRock
Damian Sousa
Cowen And Company
Susquehanna International
Point72 Asset Management

View all funds holding Taysha Gene Therapies